Nautilus Biotechnology (NAUT) Operating Margin (2026)
Nautilus Biotechnology (NAUT) posted Operating Margin of 8296.32% for Q2 2026.
Nautilus Biotechnology (NAUT) Operating Margin (2026) Analysis & Trends
Nautilus Biotechnology has reported Operating Margin for 1 years, with the latest figure at 8296.32% in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Nautilus Biotechnology | 121.99 Mn | 121.99 Mn | 175,000.00 | -8,296.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,296.32% |